ArticleFrontiers in oncology2025
Diverse radiotherapy fractionation in malignant melanoma: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant melanoma (MM) is a highly aggressive tumor, with a median overall survival (mOS) of only 8 to 12 months for its metastatic form. However, studies focusing on the efficacy of different radiotherapy (RT) fractionation regimens for MM are limited. Here, we report the case of a 60-year-old male who presented with a one-month history of intermittent abdominal pain and was subsequently diagnosed with MM. Following disease progression on systemic therapy, the patient was treated with different fractionation regimens, including 5 Gy per fraction and 3 Gy per fraction. After the failure of immunotherapy, RT effectively controlled the tumor burden. Notably, the patient received different doses of RT and achieved different outcomes. This case report demonstrates that RT could serve as a viable option for patients who have developed resistance to immunotherapy and low-dose RT may enhance tumor immune response when combined with immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.